ATORVASTATIN CALCIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atorvastatin Calcium, and what generic alternatives are available?
Atorvastatin Calcium is a drug marketed by Accord Hlthcare, Agnitio, Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Dr Reddys, Dr Reddys Labs Ltd, Graviti Pharms, Hetero Labs Ltd V, Invagen Pharms, Lannett Co Inc, Laurus, Lepu Pharm, Lupin Ltd, Macleods Pharms Ltd, Mankind Pharma, Micro Labs Ltd India, MSN, Mylan Pharms Inc, Perrigo R And D, Sandoz Inc, Sciegen Pharms Inc, Shandong Xinhua, Strides Pharma, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Usa, Umedica, and Zydus Pharms. and is included in thirty-two NDAs.
The generic ingredient in ATORVASTATIN CALCIUM is atorvastatin calcium. There are sixty-two drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atorvastatin Calcium
A generic version of ATORVASTATIN CALCIUM was approved as atorvastatin calcium by SUN PHARM INDS LTD on November 30th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATORVASTATIN CALCIUM?
- What are the global sales for ATORVASTATIN CALCIUM?
- What is Average Wholesale Price for ATORVASTATIN CALCIUM?
Summary for ATORVASTATIN CALCIUM
| US Patents: | 0 |
| Applicants: | 31 |
| NDAs: | 32 |
| Finished Product Suppliers / Packagers: | 63 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Clinical Trials: | 71 |
| Patent Applications: | 5,492 |
| Drug Sales Revenues: | Drug sales revenues for ATORVASTATIN CALCIUM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ATORVASTATIN CALCIUM |
| What excipients (inactive ingredients) are in ATORVASTATIN CALCIUM? | ATORVASTATIN CALCIUM excipients list |
| DailyMed Link: | ATORVASTATIN CALCIUM at DailyMed |
Recent Clinical Trials for ATORVASTATIN CALCIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NewAmsterdam Pharma | Phase 1 |
| Pharma Medica Research, Inc. | Phase 1 |
| University of California, San Francisco | Phase 2 |
Pharmacology for ATORVASTATIN CALCIUM
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for ATORVASTATIN CALCIUM
Anatomical Therapeutic Chemical (ATC) Classes for ATORVASTATIN CALCIUM
US Patents and Regulatory Information for ATORVASTATIN CALCIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 217081-004 | Jan 5, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Strides Pharma | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 217634-003 | Dec 21, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hetero Labs Ltd V | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 214344-001 | Sep 12, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Dr Reddys | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 214659-004 | Jul 14, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
